A venture capital firm typically engages in pre-seed to seed round investments. The initial check size ranges from $500k to $1M, with follow-on investments possible. While the firm prefers to lead, it is open to syndicating deals. The firm invests in both Europe and the US.
The team has strong backgrounding software, AI, and algorithm. Within life sciences and healthcare, the firm is looking into tech bio, synthetic biology, computational biology, chemistry, and materials. The firm is open to hardware (diagnostics or medical device) that enables new data modalities with software insights, digital health, and therapeutic platforms, but not traditional therapeutic assets. It is indication agnostic. In terms of development stages, the firm is willing to consider opportunities as early as the pre-prototype stage, provided there are plans for patent or IP protection.
There are no specific requirements for the company or the management team. However, the firm prefers technical founders with a strong scientific background. The firm will consider taking a board seat or an observer seat on a case-by-case basis.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment